Drug Discovery@nature.com 29 November 2013

Advertisement Reichert Life Sciences Surface Plasmon Resonance (SPR) Systems - Drug discovery instruments for real-time, label-free results   Reichert SPR systems generate precise kinetics (on/off rates), affinity and thermodynamics data for lead optimization. The ultra-sensitive systems are flexible and affordable. Read citations of Reichert systems in peer-reviewed abstracts.   ReichertSPR.com  TABLE OF CONTENTS 29 November 2013 News Analysis Research Highlights Research & Reviews Careers Advertisement   Mutations and Drug Resistance Topic Editors: Jian Hui Wu and Rongtuan Lin ¦ Submission deadline: 30 May 2014 This Research Topic from Frontiers in Pharmacology highlights clinically-relevant mutations in drug targets that lead to resistance to anticancer or antivirus agents as well as current strategies in overcoming these resistances. Review articles that cover the area of anticancer or antivirus agents are invited. Find out more about contributing to this Research Topic, or even hosting your own Nature Reviews Drug Discovery is on Twitter Advertisement Nature Reviews Molecular Cell Biology  FOCUS ON QUALITY CONTROL Through exposure to internal and environmental stresses, cells are continuously at risk of accumulating molecular damage that could impair their functions. Thus, they have evolved protective quality control systems to either prevent errors from occurring, or, if damage has occurred, to detect abnormal macromolecules and initiate their repair or degradation.       News Top Chilly lab mice skew cancer studies doi:10.1038/nature.2013.14190 Room-temperature conditions cause stress, suppressing immune responses. Full Text Trial designs advance to overcome bitter pill of placebo effect doi:10.1038/nm1113-1353 Sequential parallel comparative design – two randomized trials run one after the other - will be road tested by Alkermes in the Phase III trial of their opioid modulator drug ALKS 5461 for major depressive disorder to try and overcome the placebo effect. Full Text Pharmacogenetic tests yield bonus benefit: better drug adherence doi:10.1038/nm1113-1354 A recent study showed that by providing KIF6 test results to patients on statin therapy, there was a significant reduction in the number of days in which patients omit to take their drugs regardless of what the test says. Full Text First-in-class anemia drug takes aim at Amgen’s dominion doi:10.1038/nbt1113-948b AstraZeneca and Fibrogen are hoping that their hypoxia-inducible prolyl hydrolase inhibitor FG-4592, currently in Phase III trials to treat anemia in people with chronic kidney disease, will challenge Amgen’s leading recombinant erythropoietin therapy, Epogen. Full Text Analysis Top Glucokinase alternative doi:10.1038/scibx.2013.1279 Compounds that directly activate glucokinase effectively reduce blood sugar in patients with diabetes but increase the risk of adverse hypoglycemic events. Now, researchers from Amgen have identified compounds that act via a glucokinase regulator, opening the door to a potentially safer strategy to modulate hepatic glucokinase activity. Full Text Advances in prostate cancer treatment doi:10.1038/nrd4068 This article examines current and upcoming treatment modalities and provides a market outlook for prostate cancer. Full Text Research Highlights Top Anticancer drugs: IDH2 drives cancer in vivo doi:10.1038/nrd4160 Two recent studies show that mutations in the metabolic gene isocitrate dehydrogenase 2 (IDH2) can drive the development of leukaemia and sarcoma in vivo. Full Text Neurodegenerative disorders: A PIR-fect storm doi:10.1038/nrd4159 This study shows that ‘immune receptors’ may have a role in Alzheimer’s disease and points to leukocyte immunoglobulin-like receptor B2 (LILRB2) as a potential therapeutic target for this disorder. Full Text Lysosomal storage diseases: Thioesterase mimetic reduces toxicity doi:10.1038/nrd4156 This study reports a small hydroxylamine derivative that delayed neurological deterioration and extended lifespan in a mouse model of infantile neuronal ceroid lipofuscinosis (INCL) - a neurodegenerative lysosomal storage disease. Full Text Research & Reviews Top Metabolic targets for cancer therapy doi:10.1038/nrd4145 Here, the authors discuss the intimate relationship between metabolism and malignancy, focusing on therapeutic strategies and emerging agents targeting the metabolic rearrangements of cancer cells. Full Text Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain doi:10.1038/nrd3893 Glycine transporters are important regulators of the level of glycine, which can act as both an inhibitory neurotransmitter and a modulator of neuronal excitation. Here, the authors discuss the potential of glycine transporters as novel therapeutic targets for schizophrenia, alcohol dependence and pain. Full Text Immunological functions of the neuropilins and plexins as receptors for semaphorins doi:10.1038/nri3545 Semaphorins and their primary receptors, the neuropilins and plexins, participate in a wide range of innate and adaptive immune responses, which has implications for immune disorders such as multiple sclerosis, rheumatoid arthritis and allergy. Full Text Microbiota-mediated colonization resistance against intestinal pathogens doi:10.1038/nri3535 Colonization resistance - protection from exogenous pathogens by commensal bacteria - can be mediated by direct antagonism and by indirect effects on the host immune response. This Review outlines our current knowledge of immune-mediated colonization resistance against clinically relevant, antibiotic-resistant intestinal pathogens and how insights into commensal bacterial species and their mechanisms might be therapeutically used to restore resistance. Full Text Drug Discovery JOBS of the week Staff Scientist - Aerosol Drug Delivery Wyss Institute for Biologically Inspired Engineering PhD students and postdoctoral researchers positions in Drug Discovery Shanghai Jiao Tong University Imaging of control drug release materials using hyperpolarised 129Xe MRI The University of Nottingham Postdoc Position � Cancer Drug Resistance Brigham & Women's Hospital - Harvard Medical School Computational Chemist Royal Society of Chemistry (RSC) More Science jobs from Drug Discovery EVENT The Biology of Aging: Novel Drug Targets for Neurodegenerative Disease 09.05.14 New York, US More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.